Pharming Group N.V. (PHAR) Form 6-K — Oct 14, 2026
Pharming Group presented positive Phase II topline data for leniolisib in genetically identifiable primary immunodeficiencies with immune dysregulation at ESID 2026, the first clinical data for the drug beyond APDS. In the 13-participant open-label study, leniolisib was well tolerated with no new safety signals, delivering a mean 26.4% spleen volume reduction, 33.7% lymph node lesion reduction, and an 8.0% mean DLCO improvement in lung-impaired participants. All 12 completers joined a three-year extension study.
Key figures
- Dlco increase
- 8.0% mean in impaired gas exchange participants (n=7)
- Participants enrolled
- 13
- Spleen volume reduction
- 26.4% mean (n=11)
- Extension study enrolled
- all 12 completers (NCT06990529)
- Apds prevalence per million
- 1.5
- Cvid prevalence per million
- 39
- Lymph node index lesion reduction
- 33.7% mean (n=4)
- Genetic pid prevalence per million
- 7.5
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.